靶向BCMA的mRNA CAR-T细胞疗法治疗重症肌无力:安慰剂对照2b期试验的探索性生物标志物分析
本文报告了一项安慰剂对照、双盲、随机2b期试验的预设探索性分析,纳入全身型重症肌无力患者,接受Descartes-08(自体RNA编码抗BCMA CAR-T细胞疗法)治疗。在66.7%(n=10/15)的患者中,门诊环境下不进行淋巴细胞清除的短暂BCMA靶向治疗产生了持久临床疗效。流式细胞术、血清谱、多重细胞因子分析和批量/单细胞转录分析显示,Descartes-08治疗组(n≤19)与安慰剂组(n≤15)相比出现精确的自身反应性重调,表现为促免疫功能增加、BCMA+浆细胞和浆细胞样树突状细胞活性降低以及疾病相关细胞因子(如IL-6)减少,且无免疫抑制证据。
要点
- 门诊不进行淋巴细胞清除的Descartes-08在66.7%(10/15)患者中产生持久临床疗效。
- Descartes-08治疗组较安慰剂组显示促免疫功能增加、BCMA+浆细胞和pDC活性降低、IL-6等疾病相关细胞因子减少。
- 抗体和T细胞受体分析显示Descartes-08参与者自身反应性抗体和T细胞克隆循环库改变,且无疫苗特异性抗体下降或低丙种球蛋白血症。
核心结论
- Descartes-08短暂靶向BCMA可实现持久临床疗效,并揭示一种新型免疫重置,支持BCMA靶向RNA细胞疗法作为更易获取的自身免疫病疗法进行开发。
研究设计与样本
- 一项成功的安慰剂对照、双盲、随机2b期试验的预设探索性分析,纳入全身型重症肌无力患者,接受Descartes-08(自体RNA编码抗BCMA CAR-T细胞疗法)。
- Descartes-08治疗组n≤19,安慰剂组n≤15。
- 临床试验注册号NCT04146051。
主要发现
- 66.7%(n=10/15)的患者在门诊环境下不进行淋巴细胞清除接受Descartes-08后出现持久临床疗效。
- 流式细胞术、血清谱、多重细胞因子分析和批量/单细胞转录分析显示,Descartes-08治疗组较安慰剂组促免疫功能增加、BCMA+浆细胞和浆细胞样树突状细胞活性降低、IL-6等疾病相关细胞因子减少。
- 抗体和T细胞受体分析显示Descartes-08参与者自身反应性抗体和T细胞克隆的循环库发生改变。
- 这些效应发生无免疫抑制,表现为疫苗特异性抗体无下降或低丙种球蛋白血症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR)-T cell therapies have the potential to transform treatment of autoimmune disease by resetting the immune system. However, adoption of cell therapies in the autoimmune space is limited by hurdles such as inpatient administration, lymphodepletion and safety concerns around cytokine release syndrome and non-specific immunosuppression. RNA-based cell therapy has potential to address these limitations. Here we report prespecified exploratory analyses from a successful placebo-controlled, double-blind, randomized phase 2b trial in patients with generalized myasthenia gravis who received Descartes-08, an autologous, RNA-encoded anti-B cell maturation antigen (BCMA) CAR-T cell therapy. In 66.7% of patients (n = 10/15), transient targeting of BCMA with Descartes-08 administered in an outpatient setting without lymphodepletion resulted in durable clinical efficacy. Comparison of Descartes-08-treated (n ≤ 19) and placebo (n ≤ 15) cohorts by flow cytometry, serum profiling, multiplexing cytokine analysis and bulk/single-cell transcriptional analysis reveals a precision retuning of self-reactivity demonstrated by increased pro-immune function, decreased activity of BCMA+ plasma cells and plasmacytoid dendritic cells and reductions in disease-associated cytokines, such as IL-6. Furthermore, antibody and T cell receptor analysis revealed altered circulating repertoires of self-reactive antibodies and T cell clones among Descartes-08 participants. These effects occurred without immune suppression, indicated by the lack of decline in vaccine-specific antibodies or hypogammaglobulinemia. Our findings unveil a new type of immune reset and support the development of BCMA-targeted RNA cell therapies as a more accessible therapy for autoimmune diseases. ClinicalTrials.gov identifier: NCT04146051 .
引用
- Fedak RR, Ruggerie RN, Shan Y, et al. BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial. Nat Med. 2026. PMID: 41514039. doi:10.1038/s41591-025-04170-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。